Abstract:Tuberous sclerosis complex (TSC) is an autosomal dominant syndrome associated with tumors of the brain, heart, kidney, and lung. The TSC protein complex inhibits the mammalian or mechanistic target of rapamycin complex 1 (mTORC1). Inhibitors of mTORC1, including rapamycin, induce a cytostatic response in TSC tumors, resulting in temporary disease stabilization and prompt regrowth when treatment is stopped. The lack of TSC-specific cytotoxic therapies represents an important unmet clinical need. Using a high-throughput chemical screen in TSC2-deficient, patient-derived cells, we identified a series of molecules antagonized by rapamycin and therefore selective for cells with mTORC1 hyperactivity. In particular, the cell-permeable alkaloid chelerythrine induced reactive oxygen species (ROS) and depleted glutathione (GSH) selectively in TSC2-null cells based on metabolic profiling. N-acetylcysteine or GSH cotreatment protected TSC2-null cells from chelerythrine's effects, indicating that chelerythrine-induced cell death is ROS dependent. Induction of heme-oxygenase-1 (HMOX1/HO-1) with hemin also blocked chelerythrine-induced cell death. In vivo, chelerythrine inhibited the growth of TSC2-null xenograft tumors with no evidence of systemic toxicity with daily treatment over an extended period of time. This study reports the results of a bioactive compound screen and the identification of a potential lead candidate that acts via a novel oxidative stress-dependent mechanism to selectively induce necroptosis in TSC2-deficient tumors. (C) 2014 AACR.

Supplementary Figure 3 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

Supplementary Figure 7 from Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide

Supplementary Figure from Disrupting the MYC-TFEB Circuit Impairs Amino Acid Homeostasis and Provokes Metabolic Anergy

Figure S2 Inhibition of Mtorc1 and Glutamate Cysteine Ligase Induces Cytotoxicity in Tsc2-/- MEFs from Mtorc1-Driven Tumor Cells Are Highly Sensitive to Therapeutic Targeting by Antagonists of Oxidative Stress

Supplementary Table 2 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Supplementary Table 3 from Synergistic Activities of MET/RON Inhibitor BMS-777607 and Mtor Inhibitor AZD8055 to Polyploid Cells Derived from Pancreatic Cancer and Cancer Stem Cells

Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer.

Supplementary Figure 2 from the Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Impaired autophagy due to constitutive mTOR activation sensitizes TSC2-null cells to cell death under stress.

Supplemental Figure 2 from Mitochondrial Uncoupling Inhibits Reductive Carboxylation in Cancer Cells

Supplementary Figures from AMPK Alpha-1 Intrinsically Regulates the Function and Differentiation of Tumor Myeloid-Derived Suppressor Cells

Supplementary Table 1 from Serine Catabolism Regulates Mitochondrial Redox Control during Hypoxia

High-throughput drug screen identifies chelerythrine as a selective inducer of death in a TSC2-null setting.

Supplementary Figure 1 from Autophagy Activation in Hepatocellular Carcinoma Contributes to the Tolerance of Oxaliplatin Via Reactive Oxygen Species Modulation

Supplementary Data File from ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition

Supplementary Materials from ATP-Citrate Lyase Epigenetically Potentiates Oxidative Phosphorylation to Promote Melanoma Growth and Adaptive Resistance to MAPK Inhibition

Supplementary Figure 3 from the Nedd8-Activating Enzyme Inhibitor MLN4924 Induces Autophagy and Apoptosis to Suppress Liver Cancer Cell Growth

Supplementary Figure 5 from A Diverse Array of Cancer-Associated <i>mtor</i> Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity

Supplementary Fig. 7 from Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment

Supplementary Figure 4 from Niclosamide Overcomes Acquired Resistance to Erlotinib Through Suppression of STAT3 in Non–Small Cell Lung Cancer

Supplementary Figure 6 from A Diverse Array of Cancer-Associated MTOR Mutations Are Hyperactivating and Can Predict Rapamycin Sensitivity